US 10894044
Combination of topoisomerase-I inhibitors with immunotherapy in the treatment of cancer
granted A61KA61K2039/505A61K2039/507
Quick answer
US patent 10894044 (Combination of topoisomerase-I inhibitors with immunotherapy in the treatment of cancer) held by The Board of Regents of the University of Texas System expires Mon Jan 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Jan 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 12
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K2039/545, A61K2300/00